Compare Eli Lilly And Co (LLY) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs ProShares Ultra QQQ ETF — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while ProShares Ultra QQQ ETF trades at $98.47 (market cap $15.38B). The key difference: Eli Lilly And Co is far larger — about 67.6× ProShares Ultra QQQ ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and ProShares Ultra QQQ ETF for 36 Days on average.
| LLY | QLD | |
|---|---|---|
Market Cap | $1.04T | $15.38B |
Volume | 3,064,878 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.28K | $100.77 |
52-Week Low | $799.57 | $57.16 |
Typical Hold Time | 93 Days | 36 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
QLD, the ProShares Ultra QQQ ETF, trades at $98.43, down 1.8% on the day, with a bullish technical signal driven by moving averages. The ETF aims to deliver twice the daily return of the Nasdaq-100 Index. Recent news highlights its resilience compared to higher-leverage counterparts during market downturns, with institutional buying noted in Q2 2026.
The outlook hinges on Nasdaq-100 performance and Federal Reserve policy, with support at $96 and resistance at $100. Risks include market volatility and leverage decay. Analyst sentiment is mixed, advising caution until technical confirmation above key moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
